New Feature: 'QbD Process Development Function' Added to Epistra Accelerate
Simultaneously Understand Robust Conditions and Design Space
The QbD Process Development function addresses the following challenges in production condition determination:
- Challenge 1: “Performance becomes unstable due to slight experimental variability or scale-up changes, leading to poor reproducibility”
- Challenge 2: “Determining acceptable ranges and design space requires significant time and resources”
These challenges caused delays and cost increases when condition revisions were needed during later development phases.
Streamlining the Research Timeline
The new function optimizes both condition exploration and design space estimation, significantly shortening development timelines.
Case Study: Joint Research with Astellas Pharma
Joint research with Astellas Pharma achieved “50- to 100-fold efficiency improvement” and design space estimation. The results were presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, demonstrating the integration of AI and robotics in automating stem cell culture processes. Key achievements include a “50- to 100-fold increase in NK cell yield” and successful design space estimation in just three experiments.
Two Solution Approaches
Robust Optimization
AI identifies conditions that maintain stable quality even with parameter variations. “Robust conditions” are automatically derived from optimization data.
Design Space Visualization
Acceptable parameter ranges are displayed as contour plots, enabling practical Quality by Design implementation with fewer experiments than conventional approaches.
Related Articles
Won Grand Prix in the 7th IP BASE AWARD Startup Category Hosted by the Japan Patent Office
On March 3, 2026, Epistra Inc. won the Grand Prix in the startup category at the '7th IP BASE AWARD' ceremony hosted by the Japan Patent Office.
Jikkenigaku Special Issue 'AI and Data-Driven Drug Discovery Research' Published — CTO Tsuzuki Authors Chapter on AI-Driven Drug Target Discovery
In 'Jikkenigaku Special Issue: AI and Data-Driven Drug Discovery Research' published by Yodosha, our CTO Taku Tsuzuki authored a chapter on AI-driven knowledge mining for drug target discovery.
Speaking Engagement: Delivered Keynote at the 10th Cell Manufacturing Kotozukuri Symposium
On March 4, 2026, CEO Yosuke Ozawa delivered a keynote speech on optimizing cell manufacturing processes using AI and robotics at the '10th Cell Manufacturing Kotozukuri Symposium' hosted by Osaka University.